Xponance’s VistaGen Therapeutics VTGN Stock Holding History

Xponance’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-380	Closed	-$1.42K	–	1297
2023 Q1	$1.42K	Hold	380	–	–	﹤0.01%	1242
2022 Q4	$1.17K	Buy	380 +25	+7%	+$94	﹤0.01%	1234
2022 Q3	$2K	Buy	355 +3	+0.9%	+$30	﹤0.01%	1192
2022 Q2	$9K	Buy	+352	New	+$12.4K	﹤0.01%	1189
2021 Q3	–	Sell	-349	Closed	-$33K	–	1237
2021 Q2	$33K	Buy	+349	New	+$25.9K	﹤0.01%	1236

Other funds holding VTGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Xponance's VTGN Position: Q2 2023 in Review

Xponance sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 380 shares — an estimated $1.42K sold.

Xponance first reported a position in VTGN in Q2 2021 and held it in 5 quarters. The position peaked at $33K in Q2 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

Xponance reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
Xponance sold 380 VistaGen Therapeutics shares in Q2 2023, an estimated $1.42K.
Xponance first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 5 quarters.
Xponance's VistaGen Therapeutics position peaked at $33K in Q2 2021.
33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Xponance's 13F filing for Q2 2023, filed 14 Jul 2023.